Eli Lilly Acquires Versanis, the Obesity Drug Maker, for $1.9 Billion.
Eli Lilly, a pharmaceutical giant, announced its plans to acquire Versanis, a privately held obesity drug maker. The acquisition is valued at up to $1.93 billion and aims to enhance Eli Lilly’s weight loss treatment portfolio.
The agreement involves a cash payment to Versanis shareholders, including an initial upfront cost, with the possibility of additional charges based on Versanis’ achievement of specific “development and sales milestones.”
Versanis, a biotech company based in Oakland, California, has become the target of an acquisition by pharmaceutical giant Eli Lilly. Established in 2021 by biotech investment firm Aditum Bio, Versanis specializes in developing drugs for obesity and potentially other medical conditions.
The acquisition, valued at up to $1.93 billion, is part of Eli Lilly’s strategic move to expand its weight loss treatment portfolio.
The acquisition news positively impacted Eli Lilly’s stock price, which rose by 3% on the announcement day. This move reflects Eli Lilly’s determination to capitalize on the booming weight loss industry, which gained momentum with the success of Novo Nordisk’s blockbuster injections, Wegovy and Ozempic, in the previous year.
Obesity remains a significant health concern, with approximately 40% of adults in the United States classified as obese. Analysts predict the global weight loss drug market could reach $100 billion by 2030. In light of these figures, Eli Lilly sees immense potential in acquiring Versanis and its promising drug candidate, bimagrumab.
Bimagrumab works by directly binding to specific cells in the body, effectively reducing fat mass. Versanis is currently conducting a phase two trial of bimagrumab in overweight or obese adults and comparing its efficacy with Novo Nordisk’s Wegovy and Ozempic.
It’s important to note that bimagrumab operates differently from Novo Nordisk’s drugs and similar treatments developed by Eli Lilly. The latter drugs, known as GLP-1 agonists, mimic the actions of gut hormones called incretins to suppress appetite.
Versanis believes combining bimagrumab with incretin-based therapies could yield better outcomes for individuals living with obesity and associated cardiometabolic conditions. These conditions encompass diabetes, kidney disease, and heart disorders.
By exploring such synergies, Versanis aims to offer a more comprehensive and practical treatment approach.
In summary, Eli Lilly’s acquisition of Versanis represents a significant step toward expanding its weight loss treatment portfolio. With the rising prevalence of obesity worldwide, the global weight loss drug market is poised for substantial growth.
Versanis’ innovative drug candidate, bimagrumab, offers a unique mechanism of action that sets it apart from existing treatments. By leveraging synergies with incretin-based therapies, Versanis aims to address the challenges faced by individuals living with obesity and cardiometabolic conditions.
In clinical trials, overweight or obese patients treated with retatrutide achieved remarkable weight loss results, with reductions of up to 24% observed after 48 weeks. These outcomes surpass the weight reduction typically achieved by other available obesity drugs.
In addition to retatrutide, Eli Lilly also focuses on developing orforglipron, an experimental obesity pill. Clinical studies have shown that overweight or obese patients treated with orforglipron experienced weight loss of up to 14.7% of their body weight after 36 weeks of treatment.
This demonstrates the potential efficacy of orforglipron as a treatment option for individuals struggling with excess weight.
Furthermore, Eli Lilly is actively pursuing the approval of Mounjaro, their Type 2 diabetes treatment, to indicate obesity. This shows the company’s dedication to exploring innovative approaches to address obesity, recognizing the close connection between obesity and metabolic disorders such as diabetes.
By investing in developing multiple obesity treatments, including retatrutide, orforglipron, and potentially repurposing Mounjaro, Eli Lilly aims to offer a comprehensive range of therapeutic options to address the complex challenges associated with obesity.
These efforts highlight the company’s commitment to improve health and well-being of individuals affected by obesity and their dedication to making meaningful advancements in weight management.
